FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180650959> ?p ?o ?g. }

• W3180650959 endingPage "588" @default.
• W3180650959 startingPage "588" @default.
• W3180650959 abstract "Abstract Introduction: Unlike tissue biopsy, liquid biopsy allows the routine, repeat characterization of cancer at genetic, transcriptional and protein levels. Isolation of circulating tumor cells (CTCs) from a blood draw offers the potential for cancer screening, management and monitoring. Most CTC isolation systems are based on epitope-dependent CTC capture using epithelial markers. However, it is known that tumor cells can undergo epithelial-to-mesenchymal transition (EMT) when extravasating from the primary tumor to enter the bloodstream and eventually establish distant metastases. Epitope-dependent CTC detection platforms have limited sensitivity for detection of mesenchymal CTCs, leading to the inability to harvest clinically relevant CTCs for analysis, particularly in cancers with high mesenchymal phenotype such as non-small cell lung cancer (NSCLC). We developed a research use only assay for enrichment and identification of CTCs based on epithelial and mesenchymal markers using the Parsortix® system, a label-independent microfluidic device that isolates cells based on their size and compressibility. Methods: Peripheral blood (8 – 10mL) was drawn into K2EDTA tubes from 47 metastatic breast cancer (MBC) patients and 48 metastatic NSCLC patients and processed on Parsortix systems within 36 hours after collection. Harvested CTCs were cytospun and immunofluorescently stained using an optimized panel of antibodies for detection of epithelial and mesenchymal markers. Stained slides were imaged using a BioView AllegroPlus automated imaging system. Results: CTCs were captured from both MBC and NSCLC patients. 330 CTCs were identified from 19 MBC patients (mean: 17; range: 1-96). 58 CTCs were identified from 15 NSCLC patients (mean: 4; range: 1-22). Similarly, CTC clusters were observed in 63% (12/19) of the CTC-positive MBC patients and in 33% (5/15) of CTC-positive NSCLC patients. Cluster size ranged from 2-22 CTCs per cluster (2-17 in MBC and 2-22 in NSCLC), and the number of clusters per patient ranged from 1-13 in MBC and 1-2 in NSCLC. Phenotypically, more CTCs expressing only mesenchymal markers were harvested from NSCLC patients compared to MBC patients (38% vs 25%), with a larger proportion of CTCs expressing both epithelial and mesenchymal markers being harvested in both cancer types (59% in NSCLC and 74% in MBC). Only a small percentage of the CTCs harvested expressed just the epithelial markers. Conclusions: This study highlights the importance of the inclusion of mesenchymal markers into CTC characterization, as the majority of the CTCs captured by the Parsortix system from MBC and NSCLC patients expressed mesenchymal markers. The assay developed in this study successfully allowed phenotyping of the harvested cells using epithelial AND mesenchymal markers, with the results suggesting that a large proportion of the CTCs harvested would have been missed with an epithelial-only based approach, particularly in NSCLC. Citation Format: Mariacristina Ciccioli, Natalia Bravo-Santano, Amy Davis, Jolie Lewis, Ross Malcolm, Anne-Sophie Pailhes-Jimenez. Mesenchymal markers: The new avenue for circulating tumor cells detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 588." @default.
• W3180650959 created "2021-07-19" @default.
• W3180650959 creator A5020823576 @default.
• W3180650959 creator A5027465363 @default.
• W3180650959 creator A5034992992 @default.
• W3180650959 creator A5048768961 @default.
• W3180650959 creator A5059795126 @default.
• W3180650959 creator A5071614073 @default.
• W3180650959 date "2021-07-01" @default.
• W3180650959 modified "2023-09-23" @default.
• W3180650959 title "Abstract 588: Mesenchymal markers: The new avenue for circulating tumor cells detection" @default.
• W3180650959 doi "https://doi.org/10.1158/1538-7445.am2021-588" @default.
• W3180650959 hasPublicationYear "2021" @default.
• W3180650959 type Work @default.
• W3180650959 sameAs 3180650959 @default.
• W3180650959 citedByCount "2" @default.
• W3180650959 countsByYear W31806509592022 @default.
• W3180650959 countsByYear W31806509592023 @default.
• W3180650959 crossrefType "journal-article" @default.
• W3180650959 hasAuthorship W3180650959A5020823576 @default.
• W3180650959 hasAuthorship W3180650959A5027465363 @default.
• W3180650959 hasAuthorship W3180650959A5034992992 @default.
• W3180650959 hasAuthorship W3180650959A5048768961 @default.
• W3180650959 hasAuthorship W3180650959A5059795126 @default.
• W3180650959 hasAuthorship W3180650959A5071614073 @default.
• W3180650959 hasConcept C121608353 @default.
• W3180650959 hasConcept C126322002 @default.
• W3180650959 hasConcept C142724271 @default.
• W3180650959 hasConcept C143998085 @default.
• W3180650959 hasConcept C198826908 @default.
• W3180650959 hasConcept C2775930923 @default.
• W3180650959 hasConcept C2775934546 @default.
• W3180650959 hasConcept C2776256026 @default.
• W3180650959 hasConcept C2779013556 @default.
• W3180650959 hasConcept C2779529041 @default.
• W3180650959 hasConcept C502942594 @default.
• W3180650959 hasConcept C530470458 @default.
• W3180650959 hasConcept C61238886 @default.
• W3180650959 hasConcept C71924100 @default.
• W3180650959 hasConceptScore W3180650959C121608353 @default.
• W3180650959 hasConceptScore W3180650959C126322002 @default.
• W3180650959 hasConceptScore W3180650959C142724271 @default.
• W3180650959 hasConceptScore W3180650959C143998085 @default.
• W3180650959 hasConceptScore W3180650959C198826908 @default.
• W3180650959 hasConceptScore W3180650959C2775930923 @default.
• W3180650959 hasConceptScore W3180650959C2775934546 @default.
• W3180650959 hasConceptScore W3180650959C2776256026 @default.
• W3180650959 hasConceptScore W3180650959C2779013556 @default.
• W3180650959 hasConceptScore W3180650959C2779529041 @default.
• W3180650959 hasConceptScore W3180650959C502942594 @default.
• W3180650959 hasConceptScore W3180650959C530470458 @default.
• W3180650959 hasConceptScore W3180650959C61238886 @default.
• W3180650959 hasConceptScore W3180650959C71924100 @default.
• W3180650959 hasIssue "13_Supplement" @default.
• W3180650959 hasLocation W31806509591 @default.
• W3180650959 hasOpenAccess W3180650959 @default.
• W3180650959 hasPrimaryLocation W31806509591 @default.
• W3180650959 hasRelatedWork W2278221216 @default.
• W3180650959 hasRelatedWork W2395906155 @default.
• W3180650959 hasRelatedWork W2408995019 @default.
• W3180650959 hasRelatedWork W2904294837 @default.
• W3180650959 hasRelatedWork W3028445690 @default.
• W3180650959 hasRelatedWork W3029946322 @default.
• W3180650959 hasRelatedWork W3031175533 @default.
• W3180650959 hasRelatedWork W3197299853 @default.
• W3180650959 hasRelatedWork W3209475169 @default.
• W3180650959 hasRelatedWork W4281621673 @default.
• W3180650959 hasVolume "81" @default.
• W3180650959 isParatext "false" @default.
• W3180650959 isRetracted "false" @default.
• W3180650959 magId "3180650959" @default.
• W3180650959 workType "article" @default.